<DOC>
	<DOCNO>NCT00642512</DOCNO>
	<brief_summary>The primary purpose study determine efficacy oral dronabinol versus standard ondansetron antiemetic therapy prevent delayed-onset chemotherapy-induced nausea vomiting ( CINV ) retch measure incidence total response nausea vomit and/or retch follow administration moderate-to-high emetogenic chemotherapeutic agent .</brief_summary>
	<brief_title>Dronabinol Versus Standard Ondansetron Antiemetic Therapy Preventing Delayed-Onset Chemotherapy-Induced Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Histological evidence nonCNS malignancy ( primary metastatic disease ) lymphoma involve bone marrow . Undergoing single multiple day chemotherapy long Day 1 chemotherapy include : 1. moderatetohigh emetogenic regimen , 2. oxaliplatin dos employ treatment colon cancer , 3. combination AC [ Adriamycin√í ( 60 mg/m2 ) cyclophosphamide ( 600 mg/m2 ) ] use chemotherapeutic drug regimen involve taxanes treatment breast cancer . Chemotherapy agent fall low ( Level 1 ) , moderatetolow ( Level 2 ) , moderate ( Level 3 ) unless use combination Level 4 chemotherapy agent Day 1 study . Chemotherapy agent fall high ( Level 5 ) classification study . Any combination chemotherapy agent fall moderatetohigh ( Level 4 ) classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>CINV</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>retch</keyword>
</DOC>